nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—Basal cell carcinoma—Octreotide—thymus cancer	0.0607	0.124	CcSEcCtD
Dabrafenib—NEK11—thyroid gland—thymus cancer	0.0248	0.0647	CbGeAlD
Dabrafenib—NEK11—lung—thymus cancer	0.0225	0.0588	CbGeAlD
Dabrafenib—LIMK1—Semaphorin interactions—DPYSL5—thymus cancer	0.0191	0.151	CbGpPWpGaD
Dabrafenib—LIMK1—thyroid gland—thymus cancer	0.0177	0.0463	CbGeAlD
Dabrafenib—Neoplasm malignant—Octreotide—thymus cancer	0.0168	0.0341	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Octreotide—thymus cancer	0.0157	0.032	CcSEcCtD
Dabrafenib—Cellulitis—Octreotide—thymus cancer	0.0157	0.032	CcSEcCtD
Dabrafenib—Oropharyngeal pain—Octreotide—thymus cancer	0.0157	0.032	CcSEcCtD
Dabrafenib—NEK11—lymph node—thymus cancer	0.0154	0.0402	CbGeAlD
Dabrafenib—RAF1—neck—thymus cancer	0.0153	0.04	CbGeAlD
Dabrafenib—SIK1—hematopoietic system—thymus cancer	0.0143	0.0374	CbGeAlD
Dabrafenib—Phosphatase alkaline increased—Octreotide—thymus cancer	0.0143	0.0291	CcSEcCtD
Dabrafenib—Hyperkalaemia—Octreotide—thymus cancer	0.0141	0.0286	CcSEcCtD
Dabrafenib—Influenza like illness—Octreotide—thymus cancer	0.0139	0.0283	CcSEcCtD
Dabrafenib—BRAF—pituitary gland—thymus cancer	0.0127	0.0332	CbGeAlD
Dabrafenib—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.0119	0.0243	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Octreotide—thymus cancer	0.0115	0.0233	CcSEcCtD
Dabrafenib—RAF1—hematopoietic system—thymus cancer	0.0114	0.0298	CbGeAlD
Dabrafenib—LIMK1—lymph node—thymus cancer	0.011	0.0288	CbGeAlD
Dabrafenib—BRAF—bone marrow—thymus cancer	0.011	0.0287	CbGeAlD
Dabrafenib—BRAF—thyroid gland—thymus cancer	0.0109	0.0286	CbGeAlD
Dabrafenib—SLCO1B3—pituitary gland—thymus cancer	0.0109	0.0286	CbGeAlD
Dabrafenib—SIK1—cardiac atrium—thymus cancer	0.0109	0.0284	CbGeAlD
Dabrafenib—SIK1—pituitary gland—thymus cancer	0.0106	0.0278	CbGeAlD
Dabrafenib—RAF1—epithelium—thymus cancer	0.0104	0.0272	CbGeAlD
Dabrafenib—Pain in extremity—Octreotide—thymus cancer	0.0104	0.0212	CcSEcCtD
Dabrafenib—SIK1—lymphoid tissue—thymus cancer	0.0101	0.0264	CbGeAlD
Dabrafenib—BRAF—lung—thymus cancer	0.00995	0.026	CbGeAlD
Dabrafenib—Dehydration—Octreotide—thymus cancer	0.00966	0.0197	CcSEcCtD
Dabrafenib—Dry skin—Octreotide—thymus cancer	0.00952	0.0194	CcSEcCtD
Dabrafenib—Abdominal pain upper—Octreotide—thymus cancer	0.00949	0.0193	CcSEcCtD
Dabrafenib—Nasopharyngitis—Octreotide—thymus cancer	0.00929	0.0189	CcSEcCtD
Dabrafenib—SIK1—bone marrow—thymus cancer	0.00919	0.024	CbGeAlD
Dabrafenib—SIK1—thyroid gland—thymus cancer	0.00917	0.0239	CbGeAlD
Dabrafenib—Pancreatitis—Octreotide—thymus cancer	0.0088	0.0179	CcSEcCtD
Dabrafenib—RAF1—cardiac atrium—thymus cancer	0.00866	0.0226	CbGeAlD
Dabrafenib—Abdominal discomfort—Octreotide—thymus cancer	0.00861	0.0175	CcSEcCtD
Dabrafenib—SLCO1B3—lung—thymus cancer	0.00857	0.0224	CbGeAlD
Dabrafenib—SLCO1B1—hematopoietic system—thymus cancer	0.00854	0.0223	CbGeAlD
Dabrafenib—RAF1—pituitary gland—thymus cancer	0.00846	0.0221	CbGeAlD
Dabrafenib—SIK1—lung—thymus cancer	0.00832	0.0217	CbGeAlD
Dabrafenib—Hyperglycaemia—Octreotide—thymus cancer	0.0081	0.0165	CcSEcCtD
Dabrafenib—RAF1—lymphoid tissue—thymus cancer	0.00803	0.021	CbGeAlD
Dabrafenib—Urinary tract infection—Octreotide—thymus cancer	0.00778	0.0158	CcSEcCtD
Dabrafenib—Haematuria—Octreotide—thymus cancer	0.00763	0.0155	CcSEcCtD
Dabrafenib—Epistaxis—Octreotide—thymus cancer	0.00755	0.0154	CcSEcCtD
Dabrafenib—RAF1—bone marrow—thymus cancer	0.00731	0.0191	CbGeAlD
Dabrafenib—RAF1—thyroid gland—thymus cancer	0.0073	0.0191	CbGeAlD
Dabrafenib—Oedema peripheral—Octreotide—thymus cancer	0.00708	0.0144	CcSEcCtD
Dabrafenib—BRAF—lymph node—thymus cancer	0.0068	0.0178	CbGeAlD
Dabrafenib—SLC22A8—hematopoietic system—thymus cancer	0.00663	0.0173	CbGeAlD
Dabrafenib—RAF1—lung—thymus cancer	0.00663	0.0173	CbGeAlD
Dabrafenib—Immune system disorder—Octreotide—thymus cancer	0.00649	0.0132	CcSEcCtD
Dabrafenib—Arrhythmia—Octreotide—thymus cancer	0.00642	0.0131	CcSEcCtD
Dabrafenib—Alopecia—Octreotide—thymus cancer	0.00635	0.0129	CcSEcCtD
Dabrafenib—Mental disorder—Octreotide—thymus cancer	0.00629	0.0128	CcSEcCtD
Dabrafenib—Erythema—Octreotide—thymus cancer	0.00625	0.0127	CcSEcCtD
Dabrafenib—Malnutrition—Octreotide—thymus cancer	0.00625	0.0127	CcSEcCtD
Dabrafenib—Back pain—Octreotide—thymus cancer	0.00605	0.0123	CcSEcCtD
Dabrafenib—Muscle spasms—Octreotide—thymus cancer	0.00601	0.0122	CcSEcCtD
Dabrafenib—Vision blurred—Octreotide—thymus cancer	0.00589	0.012	CcSEcCtD
Dabrafenib—Anaemia—Octreotide—thymus cancer	0.00578	0.0118	CcSEcCtD
Dabrafenib—SIK1—lymph node—thymus cancer	0.00569	0.0149	CbGeAlD
Dabrafenib—Cough—Octreotide—thymus cancer	0.00546	0.0111	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—DPYSL5—thymus cancer	0.00542	0.0429	CbGpPWpGaD
Dabrafenib—Hypertension—Octreotide—thymus cancer	0.0054	0.011	CcSEcCtD
Dabrafenib—Myalgia—Octreotide—thymus cancer	0.00532	0.0108	CcSEcCtD
Dabrafenib—Arthralgia—Octreotide—thymus cancer	0.00532	0.0108	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00529	0.0108	CcSEcCtD
Dabrafenib—Dry mouth—Octreotide—thymus cancer	0.00521	0.0106	CcSEcCtD
Dabrafenib—Oedema—Octreotide—thymus cancer	0.0051	0.0104	CcSEcCtD
Dabrafenib—Infection—Octreotide—thymus cancer	0.00507	0.0103	CcSEcCtD
Dabrafenib—Nervous system disorder—Octreotide—thymus cancer	0.00501	0.0102	CcSEcCtD
Dabrafenib—Thrombocytopenia—Octreotide—thymus cancer	0.005	0.0102	CcSEcCtD
Dabrafenib—Skin disorder—Octreotide—thymus cancer	0.00496	0.0101	CcSEcCtD
Dabrafenib—Hyperhidrosis—Octreotide—thymus cancer	0.00493	0.01	CcSEcCtD
Dabrafenib—CYP2C8—hematopoietic system—thymus cancer	0.00485	0.0127	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00465	0.00947	CcSEcCtD
Dabrafenib—Insomnia—Octreotide—thymus cancer	0.00462	0.0094	CcSEcCtD
Dabrafenib—RAF1—lymph node—thymus cancer	0.00453	0.0118	CbGeAlD
Dabrafenib—Decreased appetite—Octreotide—thymus cancer	0.00444	0.00904	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Octreotide—thymus cancer	0.00441	0.00897	CcSEcCtD
Dabrafenib—Fatigue—Octreotide—thymus cancer	0.0044	0.00896	CcSEcCtD
Dabrafenib—Constipation—Octreotide—thymus cancer	0.00437	0.00889	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Octreotide—thymus cancer	0.00417	0.0085	CcSEcCtD
Dabrafenib—Body temperature increased—Octreotide—thymus cancer	0.00404	0.00822	CcSEcCtD
Dabrafenib—Abdominal pain—Octreotide—thymus cancer	0.00404	0.00822	CcSEcCtD
Dabrafenib—LIMK1—Developmental Biology—DPYSL5—thymus cancer	0.00387	0.0306	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Octreotide—thymus cancer	0.00376	0.00766	CcSEcCtD
Dabrafenib—Asthenia—Octreotide—thymus cancer	0.00366	0.00746	CcSEcCtD
Dabrafenib—Pruritus—Octreotide—thymus cancer	0.00361	0.00735	CcSEcCtD
Dabrafenib—CYP2C8—pituitary gland—thymus cancer	0.0036	0.00941	CbGeAlD
Dabrafenib—ABCG2—pituitary gland—thymus cancer	0.0035	0.00915	CbGeAlD
Dabrafenib—Diarrhoea—Octreotide—thymus cancer	0.00349	0.00711	CcSEcCtD
Dabrafenib—BRAF—Neuronal System—KCNA4—thymus cancer	0.00342	0.0271	CbGpPWpGaD
Dabrafenib—Dizziness—Octreotide—thymus cancer	0.00338	0.00687	CcSEcCtD
Dabrafenib—SIK1—LKB1 signaling events—TP53—thymus cancer	0.00334	0.0264	CbGpPWpGaD
Dabrafenib—CYP3A4—hematopoietic system—thymus cancer	0.00329	0.00859	CbGeAlD
Dabrafenib—Vomiting—Octreotide—thymus cancer	0.00325	0.00661	CcSEcCtD
Dabrafenib—Rash—Octreotide—thymus cancer	0.00322	0.00655	CcSEcCtD
Dabrafenib—Dermatitis—Octreotide—thymus cancer	0.00322	0.00655	CcSEcCtD
Dabrafenib—Headache—Octreotide—thymus cancer	0.0032	0.00651	CcSEcCtD
Dabrafenib—Nausea—Octreotide—thymus cancer	0.00303	0.00617	CcSEcCtD
Dabrafenib—ABCG2—bone marrow—thymus cancer	0.00303	0.0079	CbGeAlD
Dabrafenib—ABCG2—thyroid gland—thymus cancer	0.00302	0.00788	CbGeAlD
Dabrafenib—ABCG2—lung—thymus cancer	0.00274	0.00716	CbGeAlD
Dabrafenib—RAF1—Neuronal System—KCNA4—thymus cancer	0.00237	0.0188	CbGpPWpGaD
Dabrafenib—ABCB1—hematopoietic system—thymus cancer	0.00233	0.00608	CbGeAlD
Dabrafenib—BRAF—Bladder Cancer—CDKN2A—thymus cancer	0.00219	0.0173	CbGpPWpGaD
Dabrafenib—ABCB1—epithelium—thymus cancer	0.00213	0.00556	CbGeAlD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—CD8A—thymus cancer	0.00196	0.0155	CbGpPWpGaD
Dabrafenib—ABCG2—lymph node—thymus cancer	0.00187	0.0049	CbGeAlD
Dabrafenib—RAF1—Axon guidance—DPYSL5—thymus cancer	0.00187	0.0148	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—CD4—thymus cancer	0.00186	0.0147	CbGpPWpGaD
Dabrafenib—ABCB1—pituitary gland—thymus cancer	0.00173	0.00451	CbGeAlD
Dabrafenib—ABCB1—lymphoid tissue—thymus cancer	0.00164	0.00428	CbGeAlD
Dabrafenib—ABCB1—bone marrow—thymus cancer	0.00149	0.0039	CbGeAlD
Dabrafenib—ABCB1—thyroid gland—thymus cancer	0.00149	0.00389	CbGeAlD
Dabrafenib—LIMK1—Innate Immune System—CYLD—thymus cancer	0.00142	0.0112	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—TP53—thymus cancer	0.00136	0.0108	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—CD8A—thymus cancer	0.00136	0.0108	CbGpPWpGaD
Dabrafenib—ABCB1—lung—thymus cancer	0.00135	0.00353	CbGeAlD
Dabrafenib—RAF1—Developmental Biology—DPYSL5—thymus cancer	0.00134	0.0106	CbGpPWpGaD
Dabrafenib—BRAF—Estrogen signaling pathway—AKT1—thymus cancer	0.00131	0.0104	CbGpPWpGaD
Dabrafenib—LIMK1—Caspase Cascade in Apoptosis—AKT1—thymus cancer	0.00126	0.01	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—thymus cancer	0.00125	0.00992	CbGpPWpGaD
Dabrafenib—BRAF—Bladder Cancer—TP53—thymus cancer	0.00122	0.00965	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—AKT1—thymus cancer	0.00115	0.0091	CbGpPWpGaD
Dabrafenib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	0.00113	0.00894	CbGpPWpGaD
Dabrafenib—RAF1—Kit receptor signaling pathway—KIT—thymus cancer	0.00111	0.00883	CbGpPWpGaD
Dabrafenib—RAF1—IL-5 Signaling Pathway—IL2—thymus cancer	0.00107	0.00848	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CD8A—thymus cancer	0.00106	0.00839	CbGpPWpGaD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IL2—thymus cancer	0.00104	0.00821	CbGpPWpGaD
Dabrafenib—RAF1—IL-2 Signaling Pathway—IL2—thymus cancer	0.00103	0.00816	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—CDKN2A—thymus cancer	0.00101	0.00797	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—TP53—thymus cancer	0.000972	0.0077	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-2 signaling—IL2—thymus cancer	0.000941	0.00746	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—AKT1—thymus cancer	0.000927	0.00735	CbGpPWpGaD
Dabrafenib—ABCB1—lymph node—thymus cancer	0.000924	0.00241	CbGeAlD
Dabrafenib—RAF1—IL2-mediated signaling events—IL2—thymus cancer	0.000842	0.00667	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of retinoblastoma protein—CDKN2A—thymus cancer	0.000827	0.00656	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CYLD—thymus cancer	0.000826	0.00654	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—CDKN2A—thymus cancer	0.000825	0.00654	CbGpPWpGaD
Dabrafenib—RAF1—EPO Receptor Signaling—AKT1—thymus cancer	0.000819	0.00649	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—IL2—thymus cancer	0.000795	0.0063	CbGpPWpGaD
Dabrafenib—RAF1—FSH signaling pathway—AKT1—thymus cancer	0.000795	0.0063	CbGpPWpGaD
Dabrafenib—BRAF—Corticotropin-releasing hormone—IL2—thymus cancer	0.000795	0.0063	CbGpPWpGaD
Dabrafenib—RAF1—IGF1 pathway—AKT1—thymus cancer	0.000731	0.00579	CbGpPWpGaD
Dabrafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—AKT1—thymus cancer	0.000731	0.00579	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—KIT—thymus cancer	0.000718	0.00569	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IL2—thymus cancer	0.000717	0.00568	CbGpPWpGaD
Dabrafenib—RAF1—Nongenotropic Androgen signaling—AKT1—thymus cancer	0.000712	0.00564	CbGpPWpGaD
Dabrafenib—ABCG2—Fluoropyrimidine Activity—TP53—thymus cancer	0.000699	0.00554	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—CDKN2A—thymus cancer	0.000696	0.00551	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—KIT—thymus cancer	0.000669	0.0053	CbGpPWpGaD
Dabrafenib—RAF1—Class I PI3K signaling events mediated by Akt—AKT1—thymus cancer	0.000646	0.00512	CbGpPWpGaD
Dabrafenib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	0.00061	0.00483	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CD4—thymus cancer	0.000608	0.00482	CbGpPWpGaD
Dabrafenib—RAF1—CXCR3-mediated signaling events—AKT1—thymus cancer	0.000605	0.00479	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	0.000593	0.0047	CbGpPWpGaD
Dabrafenib—RAF1—IL-5 Signaling Pathway—AKT1—thymus cancer	0.00058	0.0046	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—CDKN2A—thymus cancer	0.000571	0.00452	CbGpPWpGaD
Dabrafenib—RAF1—ErbB2/ErbB3 signaling events—AKT1—thymus cancer	0.000569	0.00451	CbGpPWpGaD
Dabrafenib—BRAF—mTOR signaling pathway—AKT1—thymus cancer	0.000562	0.00445	CbGpPWpGaD
Dabrafenib—BRAF—TSH signaling pathway—AKT1—thymus cancer	0.000562	0.00445	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—TP53—thymus cancer	0.000559	0.00443	CbGpPWpGaD
Dabrafenib—RAF1—IL-2 Signaling Pathway—AKT1—thymus cancer	0.000558	0.00442	CbGpPWpGaD
Dabrafenib—RAF1—TWEAK Signaling Pathway—AKT1—thymus cancer	0.000558	0.00442	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—KIT—thymus cancer	0.000555	0.0044	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—IL2—thymus cancer	0.00055	0.00436	CbGpPWpGaD
Dabrafenib—BRAF—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—thymus cancer	0.000549	0.00435	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-11 Signaling Pathway—AKT1—thymus cancer	0.000538	0.00426	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—KIT—thymus cancer	0.000531	0.00421	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—KIT—thymus cancer	0.000523	0.00414	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—KIT—thymus cancer	0.00052	0.00412	CbGpPWpGaD
Dabrafenib—RAF1—Ceramide signaling pathway—AKT1—thymus cancer	0.000502	0.00398	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—KIT—thymus cancer	0.000499	0.00396	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—KIT—thymus cancer	0.000497	0.00394	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—KIT—thymus cancer	0.000494	0.00392	CbGpPWpGaD
Dabrafenib—RAF1—IL-3 Signaling Pathway—AKT1—thymus cancer	0.000493	0.00391	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—KIT—thymus cancer	0.000492	0.0039	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CYLD—thymus cancer	0.00049	0.00389	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL2—thymus cancer	0.000484	0.00383	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—thymus cancer	0.000478	0.00379	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	0.000472	0.00374	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—TP53—thymus cancer	0.000466	0.00369	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	0.000463	0.00367	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KIT—thymus cancer	0.000463	0.00367	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—KIT—thymus cancer	0.000463	0.00367	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TP53—thymus cancer	0.000459	0.00364	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—KIT—thymus cancer	0.000459	0.00363	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KIT—thymus cancer	0.000456	0.00361	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KIT—thymus cancer	0.000455	0.0036	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—KIT—thymus cancer	0.000453	0.00359	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.00045	0.00357	CbGpPWpGaD
Dabrafenib—BRAF—Corticotropin-releasing hormone—AKT1—thymus cancer	0.000431	0.00341	CbGpPWpGaD
Dabrafenib—RAF1—Kit receptor signaling pathway—AKT1—thymus cancer	0.000425	0.00337	CbGpPWpGaD
Dabrafenib—RAF1—Fc-epsilon receptor I signaling in mast cells—AKT1—thymus cancer	0.000414	0.00328	CbGpPWpGaD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—AKT1—thymus cancer	0.000413	0.00327	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	0.00041	0.00325	CbGpPWpGaD
Dabrafenib—RAF1—Endothelins—AKT1—thymus cancer	0.000404	0.0032	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD8A—thymus cancer	0.000403	0.0032	CbGpPWpGaD
Dabrafenib—BRAF—Integrin-mediated Cell Adhesion—AKT1—thymus cancer	0.000403	0.00319	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD4—thymus cancer	0.000398	0.00315	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—AKT1—thymus cancer	0.000394	0.00312	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—AKT1—thymus cancer	0.000389	0.00308	CbGpPWpGaD
Dabrafenib—RAF1—mTOR signaling pathway—AKT1—thymus cancer	0.000389	0.00308	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—AKT1—thymus cancer	0.000389	0.00308	CbGpPWpGaD
Dabrafenib—BRAF—ErbB1 downstream signaling—AKT1—thymus cancer	0.000388	0.00307	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—thymus cancer	0.000387	0.00307	CbGpPWpGaD
Dabrafenib—RAF1—BCR signaling pathway—AKT1—thymus cancer	0.000384	0.00304	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—thymus cancer	0.00038	0.00301	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—thymus cancer	0.000369	0.00293	CbGpPWpGaD
Dabrafenib—RAF1—Leptin signaling pathway—AKT1—thymus cancer	0.000351	0.00278	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—thymus cancer	0.000343	0.00272	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—AKT1—thymus cancer	0.000339	0.00269	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—thymus cancer	0.000333	0.00264	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	0.000327	0.00259	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.000321	0.00254	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—thymus cancer	0.000318	0.00252	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KIT—thymus cancer	0.000315	0.0025	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—thymus cancer	0.000315	0.0025	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—AKT1—thymus cancer	0.000303	0.0024	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KIT—thymus cancer	0.000303	0.0024	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAML2—thymus cancer	0.000303	0.0024	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—AKT1—thymus cancer	0.000298	0.00236	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—AKT1—thymus cancer	0.000298	0.00236	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL2—thymus cancer	0.000293	0.00232	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—AKT1—thymus cancer	0.00029	0.0023	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—AKT1—thymus cancer	0.000286	0.00226	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CYLD—thymus cancer	0.000286	0.00226	CbGpPWpGaD
Dabrafenib—RAF1—Integrin-mediated Cell Adhesion—AKT1—thymus cancer	0.000279	0.00221	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	0.000274	0.00217	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—AKT1—thymus cancer	0.000274	0.00217	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IL2—thymus cancer	0.000273	0.00216	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—AKT1—thymus cancer	0.000268	0.00213	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—AKT1—thymus cancer	0.000266	0.00211	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—thymus cancer	0.000264	0.0021	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—AKT1—thymus cancer	0.000264	0.00209	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—AKT1—thymus cancer	0.000255	0.00202	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—AKT1—thymus cancer	0.000249	0.00198	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—AKT1—thymus cancer	0.000241	0.00191	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—thymus cancer	0.000232	0.00184	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—thymus cancer	0.00023	0.00182	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	0.000226	0.00179	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—thymus cancer	0.000226	0.00179	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—AKT1—thymus cancer	0.000225	0.00178	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—AKT1—thymus cancer	0.000223	0.00177	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—thymus cancer	0.000218	0.00173	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—thymus cancer	0.000213	0.00169	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAML2—thymus cancer	0.000212	0.00168	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—AKT1—thymus cancer	0.000212	0.00168	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAML2—thymus cancer	0.000209	0.00166	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—AKT1—thymus cancer	0.000208	0.00165	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—AKT1—thymus cancer	0.000203	0.00161	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—AKT1—thymus cancer	0.000199	0.00158	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—AKT1—thymus cancer	0.000198	0.00157	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.000197	0.00156	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—AKT1—thymus cancer	0.000191	0.00152	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—AKT1—thymus cancer	0.000191	0.00151	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	0.00019	0.0015	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—AKT1—thymus cancer	0.00019	0.0015	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—AKT1—thymus cancer	0.000189	0.00149	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—AKT1—thymus cancer	0.000188	0.00149	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—AKT1—thymus cancer	0.000184	0.00146	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	0.000183	0.00145	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KIT—thymus cancer	0.00018	0.00143	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	0.000177	0.0014	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—AKT1—thymus cancer	0.000177	0.0014	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—AKT1—thymus cancer	0.000177	0.0014	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—AKT1—thymus cancer	0.000175	0.00139	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—AKT1—thymus cancer	0.000174	0.00138	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—AKT1—thymus cancer	0.000173	0.00137	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—AKT1—thymus cancer	0.000173	0.00137	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KIT—thymus cancer	0.000173	0.00137	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—AKT1—thymus cancer	0.000167	0.00132	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.000166	0.00132	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	0.000156	0.00124	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—thymus cancer	0.000148	0.00117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAML2—thymus cancer	0.000147	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—thymus cancer	0.000141	0.00111	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KIT—thymus cancer	0.00014	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—thymus cancer	0.000139	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—thymus cancer	0.000138	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—thymus cancer	0.000132	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—AKT1—thymus cancer	0.00012	0.000953	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—thymus cancer	0.000116	0.000916	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—thymus cancer	0.000107	0.000847	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIT—thymus cancer	0.000105	0.00083	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIT—thymus cancer	9.79e-05	0.000776	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KIT—thymus cancer	9.67e-05	0.000766	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	9.28e-05	0.000735	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—thymus cancer	9.03e-05	0.000715	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—thymus cancer	8.07e-05	0.000639	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—thymus cancer	8.01e-05	0.000635	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	7.84e-05	0.000621	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—thymus cancer	7.77e-05	0.000616	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—thymus cancer	7.62e-05	0.000604	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—thymus cancer	7.4e-05	0.000586	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—thymus cancer	7.37e-05	0.000584	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—thymus cancer	6.89e-05	0.000546	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—thymus cancer	6.86e-05	0.000544	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—thymus cancer	6.77e-05	0.000537	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—thymus cancer	6.59e-05	0.000522	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—thymus cancer	5.33e-05	0.000423	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—thymus cancer	4.77e-05	0.000378	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—thymus cancer	4.42e-05	0.000351	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—thymus cancer	4.37e-05	0.000347	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—thymus cancer	4.33e-05	0.000343	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—thymus cancer	4e-05	0.000317	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—thymus cancer	3.74e-05	0.000296	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—thymus cancer	3.69e-05	0.000292	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—thymus cancer	3.06e-05	0.000243	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—thymus cancer	2.91e-05	0.000231	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—thymus cancer	2.7e-05	0.000214	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—thymus cancer	2.58e-05	0.000205	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—thymus cancer	1.67e-05	0.000133	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—thymus cancer	1.46e-05	0.000115	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—thymus cancer	8.98e-06	7.12e-05	CbGpPWpGaD
